Skip to main content
Clinical Trials/NCT03379025
NCT03379025
Withdrawn
Not Applicable

Effects of Electronic Cigarettes on Smokers With Mild to Moderate Chronic Obstructive Pulmonary Disease

ConditionsCOPDTobacco Use

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COPD
Sponsor
Massachusetts General Hospital
Primary Endpoint
Change in cigarettes per day
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

This study evaluates the effects of electronic cigarette use on cigarette smoking and markers of tobacco use, as well as respiratory symptoms and function in smokers with mild to moderate chronic obstructive pulmonary disease (COPD). All participants will receive a 12 week supply of electronic cigarettes to use instead of their regular conventional cigarettes.

Detailed Description

Electronic cigarettes are devices that heat a solution containing nicotine to form an aerosol that is then inhaled by the user. Electronic cigarettes are used by many smokers, including smokers with chronic health conditions such as COPD. Given that e-cigarettes are still relatively new, their effects on health are not well defined. It is important to understand how electronic cigarettes affects symptoms and lung function in smokers with COPD to determine the short-term safety of these products. To do this, an initial step involves observing the extent to which smokers substitute their conventional cigarette use with electronic cigarette use and change their exposure to tobacco use biomarkers.

Registry
clinicaltrials.gov
Start Date
October 2019
End Date
August 2021
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sara Kalkhoran

Assistant Professor of Medicine

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • At least 10 pack year smoking history
  • Daily use of at least 5 cigarettes
  • No plan to quit cigarettes in the next 30 days
  • Willing to use e-cigarettes
  • Diagnosis of COPD (FEV1/forced vital capacity \[FVC\] \<0.70) with mild (FEV1 \>80% predicted) or moderate (FEV1 \<80% but \>50% predicted) airflow limitation (post-bronchodilator); confirmed by spirometry
  • English-speaking

Exclusion Criteria

  • Past 30-day use of nicotine-containing products (cigars, cigarillos, hookah, electronic cigarettes, smokeless tobacco, nicotine replacement therapy)
  • Past 30 day use of inhaled drugs (marijuana, crack)
  • Pregnant or breastfeeding
  • Planning to become pregnant within the next 3 months or unable to agree to use appropriate contraception during study
  • Pulmonary disease other than COPD or asthma
  • Ever requiring mechanical ventilation
  • 2 or more hospitalizations for COPD in the past 12 months
  • Cardiac hospitalization in the past 6 months
  • Active chest pain or palpitations
  • Uncontrolled hypertension (blood pressure \>160/100)

Outcomes

Primary Outcomes

Change in cigarettes per day

Time Frame: baseline and 12 weeks

Change in self-reported cigarettes per day from Week 0 to Week 12

Secondary Outcomes

  • St. George's Respiratory Questionnaire(baseline and 12 weeks)
  • Change in urine anabasine(baseline and 12 weeks)
  • Change in exhaled carbon monoxide(baseline and 12 weeks)
  • Change in urine cotinine(baseline and 12 weeks)
  • Transition Dyspnea Index(baseline and 12 weeks)
  • Change in pulmonary function(baseline and 12 weeks)

Similar Trials